Failed sickle cell gene therapy may get a second chance
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
A sickle cell gene-editing therapy developed over a decade may be revived, three years after its trial was abruptly halted when the first patient experienced a serious adverse event.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu